Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06308445 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis

Study acronym: RAPA-4-PAF
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Aug 1, 2025 to Sep 1, 2026 Primary and study completion dates: Aug 2030 to Sep 2030v3 Show 1 more changeShow less
    • Primary and study completion dates: Aug 2030 to Sep 2030
  2. Primary and study completion dates: Aug 2029 to Aug 2030 Start date: Aug 1, 2024 to Aug 1, 2025v2 Show 1 more changeShow less
    • Start date: Aug 1, 2024 to Aug 1, 2025
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The hypothesize of this research is that rapamycin is effective and well-tolerated in teenagers with familial adenomatous polyposis (FAP). Rapamycin could be effective in blocking the formation of adenomas and/or their evolution by decreasing their size and number. Researchers aim to assess the safety profile of rapamycin in FAP adolescents using a 2 low dose regimen.
Trial Details
NCT Number NCT06308445
Lead Sponsor University Hospital, Toulouse
Conditions Familial Adenomatous Polyposis
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov